OncoMatch/Clinical Trials/NCT06906887
PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer
Is NCT06906887 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Induction Chemotherapy (modified FLOT or modified FOLFOX-6) and Chemotherapy for esophageal cancer.
Treatment: Induction Chemotherapy (modified FLOT or modified FOLFOX-6) · Chemotherapy — This is a prospective, randomized, open-label, two-arm phase 2 trial that will evaluate whether the use of Pulsed Low-Dose-Rate radiation technique, as compared to standard radiation, is associated with reduced rates of clinically significant esophagitis during and following chemoradiation.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Gastric Cancer
Disease stage
Required: Stage II, III, IVB
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: chemotherapy — induction
Currently receiving or have received induction chemotherapy and planned for definitive dose chemoradiation (+/- esophagectomy)
Cannot have received: non-approved chemotherapy
Prior non-approved chemotherapy for the treatment of cancer
Cannot have received: radiation therapy
Exception: to the region of the study cancer that would result in an overlap of radiation therapy fields
Prior radiotherapy to the region of the study cancer that would result in an overlap of radiation therapy fields
Lab requirements
Blood counts
Absolute Neutrophil Count ≥ 1,500/mcg; Hemoglobin ≥ 8 gm/dL; Platelets ≥ 100,000/mcL
Kidney function
creatinine clearance of ≥ 50 ml/min as calculated by the Cockcroft-Gault equation
Liver function
total bilirubin ≤ 1.5 x ULN (patients with known Gilbert Syndrome can have a total bilirubin < 2.5 x ULN)
Adequate hematologic function within 30 days prior to registration defined as follows: Absolute Neutrophil Count ≥ 1,500/mcg; Hemoglobin ≥ 8 gm/dL; Platelets ≥ 100,000/mcL. Adequate renal function within 30 days prior to registration, defined as a creatinine clearance of ≥ 50 ml/min as calculated by the Cockcroft-Gault equation. Adequate hepatic function within 30 days prior to registration, defined as total bilirubin ≤ 1.5 x ULN. Note: patients with known Gilbert Syndrome can have a total bilirubin < 2.5 x upper limit of normal (ULN).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Froedtert & the Medical College of Wisconsin · Milwaukee, Wisconsin
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify